Dancik Yuri, Troutman John A, Jaworska Joanna
The Procter & Gamble Company, 1853 Strombeek-Bever, Belgium.
The Procter & Gamble Company, Cincinnati, OH 45253, USA.
Reprod Toxicol. 2015 Aug 1;55:50-63. doi: 10.1016/j.reprotox.2015.01.002. Epub 2015 Jan 15.
We present a quantitative in vitro-in vivo extrapolation framework enabling the estimation of the external dermal exposure dose from in vitro experimental data relevant to a toxicity pathway of interest. The framework adapts elements of the biological pathway altering dose (BPAD) method [Judson et al. Chem Res Toxicol 2011;24:451] to the case of dermal exposure. Dermal doses of four toxicants equivalent to concentrations characterizing their effect on estrogen receptor α or androgen receptor activity in chemical-activated luciferase expression (CALUX) assays are estimated. The analysis shows that dermal BPADs, calculated from one in vitro concentration, can differ by up to a factor of 55, due to the impact applied dose and dermal exposure scenarios can have on skin permeation kinetics. These features should therefore be taken into account in risk assessment of dermally applied chemicals.
我们提出了一个定量的体外-体内外推框架,能够根据与感兴趣的毒性途径相关的体外实验数据估算外部皮肤暴露剂量。该框架将生物途径改变剂量(BPAD)方法[贾德森等人,《化学研究毒理学》2011年;24:451]的要素应用于皮肤暴露的情况。估算了四种有毒物质的皮肤剂量,这些剂量相当于它们在化学激活荧光素酶表达(CALUX)试验中对雌激素受体α或雄激素受体活性产生影响的浓度。分析表明,由于应用剂量和皮肤暴露情况对皮肤渗透动力学的影响,根据一种体外浓度计算出的皮肤BPADs可能相差高达55倍。因此,在对经皮肤施用的化学品进行风险评估时应考虑这些特征。